A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

A Phase 1 Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

The main objective of this trial is to assess the safety and tolerability of AMG 127 as single dose and multiple doses in healthy participants and participants with type 2 diabetes mellitus (T2DM).

Inclusion Criteria for Part A and B

• Participant must be 18-65 years of age
• Participant must be overtly healthy

Inclusion Criteria for Part C

• Participant must be 40-75 years of age
• Confirmed diagnoses of T2DM

Exclusion Criteria for Part A and B

• History of hypotension, syncope, or orthostatic intolerance
• Systolic blood pressure >140 millimeters of mercury (mmHg) or diastolic blood pressure >90 mmHg

Exclusion Criteria for Part C

• Hemoglobin A1c (HbA1c) >10% within the last 3 months
• History of hypotension, syncope, or orthostatic intolerance
• Systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg